Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Plant Breeding and Biotechnology01:59

Plant Breeding and Biotechnology

19.8K
Crop cultivation has a long history in human civilization, with records showing the cultivation of cereal plants beginning at around 8000 BC. This early plant breeding was developed primarily to provide a steady supply of food.
19.8K
Transgenic Organisms00:53

Transgenic Organisms

31.6K
Overview
31.6K
Types of Genetic Transfer Between Organisms02:18

Types of Genetic Transfer Between Organisms

29.5K
Genetic transfer occurs when genetic information is passed from one organism to another. It occurs via two mechanisms: vertical gene transfer and horizontal gene transfer. Vertical gene transfer occurs when genetic information is transferred from one generation to the next, which happens much more frequently than horizontal gene transfer. Both sexual and asexual reproduction are forms of vertical gene transfer, where one or more organisms pass some or all of their genome onto their progeny.
29.5K
Horizontal Gene Transfer01:27

Horizontal Gene Transfer

151
Horizontal gene transfer (HGT) is a process where genetic material moves between organisms within the same generation, unlike vertical gene transfer, which occurs from parent to offspring. HGT plays a crucial role in microbial evolution, adaptation, and survival, particularly in shared environments like the human gut.Mobile genetic elements such as plasmids, prophages, integrons, insertion sequences, and transposons facilitate this process. HGT occurs through three primary mechanisms:...
151
Bioequivalence: Overview01:16

Bioequivalence: Overview

1.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.2K
Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

2.9K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Climate-driven in-situ trait variation in an annual ruderal grass across Europe.

Annals of botany·2026
Same author

The influence of metaboreflex activation on pulmonary pressure with combined chemoreflex activation in acute and chronic hypoxia.

The Journal of physiology·2026
Same author

Periprocedural pain management in pleural disease: a narrative review of current and emerging strategies.

Journal of thoracic disease·2026
Same author

Harvest Process and Affinity Resin Selection Impacts on Adeno-Associated Virus Residual Host Cell Protein Retention.

Human gene therapy·2026
Same author

Treatment with Daratumumab in Combination with Glucocorticosteroids as First-Line Treatment Achieves a Complete Remission for a Patient with Multiple Myeloma and Resolves Neutropenia: A Case Report.

Case reports in oncology·2026
Same author

Five-Year Outcomes After Prostate-Specific Membrane Antigen PET/CT-Guided Salvage Radiotherapy Following Radical Prostatectomy.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

A PAT-aligned framework for installing and operating particle counting systems to detect pre-limit particle-size distribution shifts in ISO-8 (non-sterile) controlled areas.

PDA journal of pharmaceutical science and technology·2026
Same journal

Using Positive Controls to Define the Defect Detection Range for CCIT Method Development and Validation.

PDA journal of pharmaceutical science and technology·2026
Same journal

Patient-Centric Drug Delivery: Establishing Injection Hold Time Limits for Large Volume Autoinjectors.

PDA journal of pharmaceutical science and technology·2026
Same journal

Gas flow through micro-capillaries â which flow law is most suitable to predict the flow rate through micro-capillaries?

PDA journal of pharmaceutical science and technology·2026
Same journal

Peer Review.

PDA journal of pharmaceutical science and technology·2026
Same journal

In-situ Verification of Disinfection Rotation for Contamination Control.

PDA journal of pharmaceutical science and technology·2026
See all related articles

Related Experiment Video

Updated: Sep 15, 2025

Generic Protocol for Optimization of Heterologous Protein Production Using Automated Microbioreactor Technology
06:24

Generic Protocol for Optimization of Heterologous Protein Production Using Automated Microbioreactor Technology

Published on: December 15, 2017

10.2K

Defining a Generic Technology Transfer Process for use Across the Biopharmaceutical Manufacturing Industry.

Jonathan Moore1, Diana Chinchilla-Olszar2, Mary Switzer3

  • 1Biopharmada; Gaithersburg MD, USA.

PDA Journal of Pharmaceutical Science and Technology
|July 15, 2025
PubMed
Summary
This summary is machine-generated.

Biopharmaceutical technology transfer processes lack standardization, hindering collaboration. This paper defines a generic process to improve efficiency and communication across the industry.

Keywords:
BiopharmaceuticalCommunicationManufacturingProcess DefinitionStandardizationTechnology transfer

More Related Videos

A GMP-Compliant Procedure for the Generation of Gene-Modified T cells
06:47

A GMP-Compliant Procedure for the Generation of Gene-Modified T cells

Published on: October 6, 2023

682
A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics
07:48

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics

Published on: September 22, 2011

22.4K

Related Experiment Videos

Last Updated: Sep 15, 2025

Generic Protocol for Optimization of Heterologous Protein Production Using Automated Microbioreactor Technology
06:24

Generic Protocol for Optimization of Heterologous Protein Production Using Automated Microbioreactor Technology

Published on: December 15, 2017

10.2K
A GMP-Compliant Procedure for the Generation of Gene-Modified T cells
06:47

A GMP-Compliant Procedure for the Generation of Gene-Modified T cells

Published on: October 6, 2023

682
A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics
07:48

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics

Published on: September 22, 2011

22.4K

Area of Science:

  • Biopharmaceutical Manufacturing
  • Process Engineering
  • Technology Transfer

Background:

  • Technology transfer processes vary significantly across the biopharmaceutical industry, leading to complexity and communication issues.
  • Lack of standardization and evolving industry requirements create inefficiencies and barriers to inter-organizational collaboration.
  • Rapid industry evolution with novel processes (e.g., continuous processing, new modalities) necessitates a more unified approach.

Purpose of the Study:

  • To define a generic technology transfer process applicable across the biopharmaceutical sector.
  • To provide a foundational framework that organizations can adapt and build upon.
  • To address the increasing complexity and divergence of biopharmaceutical manufacturing processes.

Main Methods:

  • Input gathered from a broad range of industry subject matter experts.
  • Development of a standardized, generic definition of the technology transfer process.
  • Focus on creating a universally applicable framework, not company-specific.

Main Results:

  • A defined generic technology transfer process has been established.
  • The process aims to mitigate inefficiencies caused by disparate organizational methods.
  • Provides a common starting point for improving technology transfer practices.

Conclusions:

  • A standardized, generic technology transfer process is essential for the evolving biopharmaceutical industry.
  • This NIIMBL-sponsored definition offers a foundation for enhanced collaboration and efficiency.
  • Further development and adoption of this generic process can streamline biopharmaceutical manufacturing transfers.